Cite
Garcia JS, Kim HT, Murdock HM, et al. Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv. 2021;5(24):5536-5545doi: 10.1182/bloodadvances.2021005566.
Garcia, J. S., Kim, H. T., Murdock, H. M., Cutler, C. S., Brock, J., Gooptu, M., Ho, V. T., Koreth, J., Nikiforow, S., Romee, R., Shapiro, R., Loschi, F., Ryan, J., Fell, G., Karp, H. Q., Lucas, F., Kim, A. S., Potter, D., Mashaka, T., Stone, R. M., DeAngelo, D. J., Letai, A., Lindsley, R. C., Soiffer, R. J., & Antin, J. H. (2021). Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood advances, 5(24), 5536-5545. https://doi.org/10.1182/bloodadvances.2021005566
Garcia, Jacqueline S, et al. "Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active." Blood advances vol. 5,24 (2021): 5536-5545. doi: https://doi.org/10.1182/bloodadvances.2021005566
Garcia JS, Kim HT, Murdock HM, Cutler CS, Brock J, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, Loschi F, Ryan J, Fell G, Karp HQ, Lucas F, Kim AS, Potter D, Mashaka T, Stone RM, DeAngelo DJ, Letai A, Lindsley RC, Soiffer RJ, Antin JH. Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 Dec 28;5(24):5536-5545. doi: 10.1182/bloodadvances.2021005566. PMID: 34614506; PMCID: PMC8714724.
Copy
Download .nbib